title: Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension.
abstract: Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen that is upregulated during exposure to hypoxia. In this study, we analyzed heart and lung VEGF mRNA expression and examined pulmonary vascular remodeling as well as myocardial capillary density in two rat models of pulmonary hypertension involving exposure to chronic hypoxia (CH) and treatment with monocrotaline (MCT), respectively. The rats were studied after 0.5, 1, 3, 15, and 30 days of exposure to 10% O2 or 1, 6, and 30 days after a subcutaneous MCT injection (60 mg/kg). Both CH and MCT induced pulmonary hypertension and hypertrophy of the right ventricle (RV) with increased RV weight and atrial natriuretic peptide mRNA expression. VEGF mRNA expression as assessed by Northern blot analysis was potently induced after 12 h of hypoxia in both the right and left ventricles. After prolonged exposure to hypoxia, VEGF mRNA returned to baseline in the left ventricle (LV) but remained increased in the RV, where it peaked after 30 days. In MCT rats, VEGF mRNA was unchanged in the LV but decreased by 50% in the RV and by 90% in the lungs after 30 days. VEGF mRNA remained unchanged in the lungs from CH rats. Pulmonary vascular remodeling was more pronounced in MCT than in CH rats. The number of capillaries per RV myocyte was increased in rats exposed to 30 days of hypoxia, whereas it remained unchanged in MCT rats despite a similar degree of RV hypertrophy. Our results suggest that the sustained increase in VEGF expression in the hypertrophied RV during CH may account for the increased number of capillaries per myocyte. In contrast, reduced VEGF expression in the lungs and RV of MCT rats may aggravate pulmonary vascular remodeling and compromise RV myocardial perfusion.
authors.affiliation: Service de Pharmacologie Clinique, Département de Physiologie, Institut National de la Santé et de la Recherche Médicale Unité 492 and 421, Hôpital Henri Mondor, 94010 Créteil, France.
authors.forename: C
authors.initials: C
authors.lastname: Partovian
authors.forename: S
authors.initials: S
authors.lastname: Adnot
authors.forename: S
authors.initials: S
authors.lastname: Eddahibi
authors.forename: E
authors.initials: E
authors.lastname: Teiger
authors.forename: M
authors.initials: M
authors.lastname: Levame
authors.forename: P
authors.initials: P
authors.lastname: Dreyfus
authors.forename: B
authors.initials: B
authors.lastname: Raffestin
authors.forename: C
authors.initials: C
authors.lastname: Frelin
mesh_terms: D000818:Animals; D002908:Chronic Disease; D016228:Endothelial Growth Factors / Q000235:genetics*; D006439:Hemodynamics / Q000502:physiology; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D000860:Hypoxia / Q000150:complications; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008222:Lymphokines / Q000235:genetics*; D008297:Male; D016686:Monocrotaline; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D009929:Organ Size / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016686:Monocrotaline